triazoles has been researched along with Local Neoplasm Recurrence in 211 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.47) | 18.2507 |
| 2000's | 102 (48.34) | 29.6817 |
| 2010's | 85 (40.28) | 24.3611 |
| 2020's | 23 (10.90) | 2.80 |
| Authors | Studies |
|---|---|
| Biran, N; Breeze, J; Chari, A; Choquet, S; Cornell, RF; Costa, L; Daniele, P; Delforge, M; Dimopoulos, MA; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Gavriatopoulou, M; Hoffman, JE; Kaminetzky, D; Kauffman, M; Laurent, F; Levy, M; Li, L; Lionel, K; Meuleman, N; Mohty, M; Moreau, P; Nooka, A; Parker, T; Podar, K; Raab, M; Richardson, P; Richter, J; Schiller, G; Schreder, M; Shacham, S; Shah, J; Siegel, D; Sundar, J; Tremblay, G; Tuchman, S; Vij, R; Vlummens, P; Vogl, D; Weisel, K | 1 |
| Ferrante, SA; Gorsh, B; Hogea, C; Hughes, R; Kapetanakis, V; Popat, R; Prawitz, T; Sarri, G; Suvannasankha, A; Wang, F; Willson, J | 1 |
| Chavez, JC; Logue, JM | 1 |
| Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC | 1 |
| Chen, SL; Chen, XQ; Dai, YJ; Hu, F; Li, XP; Liang, Y; Lu, YX; Wang, DW | 1 |
| Ben-Shahar, O; Cass, M; Kashyap, T; Landesman, Y; McDonald, AB | 1 |
| Agte, S; Aleman, A; Bhalla, S; Chari, A; Cho, HJ; Ghodke-Puranik, Y; Jagannath, S; Jiang, J; Laganà, A; Landesman, Y; Leshchenko, V; Madduri, D; Melnekoff, DT; Parekh, S; Restrepo, P; Richard, S; Richter, J; Walker, CJ | 1 |
| Andersson, M; Buch-Larsen, K; Gillberg, L; Marina, D; Rasmussen, ÅK; Schwarz, P | 1 |
| Garate, GM; Ochoa, PA; Remaggi, G | 1 |
| Cho, I; Choi, J; Park, J; Sheen, YY | 1 |
| Egawa, C; Hasegawa, Y; Higaki, K; Hozumi, Y; Iijima, K; Iwase, T; Komoike, Y; Masuoka, H; Mukai, H; Nakamura, T; Ohtani, S; Ohtsu, H; Saji, S; Sato, Y; Takei, H; Tanabe, M; Tanaka, M; Yanagita, Y | 1 |
| Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Rastogi, P; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wolmark, N | 1 |
| Gouda, MA; Thein, KZ | 1 |
| Chung, D; Diab, V; Drullinsky, P; Giralt, S; Hassoun, H; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Mailankody, S; Mastey, D; Salcedo, M; Schlossman, J; Scordo, M; Shah, G; Shah, U; Smith, E; Werner, K | 1 |
| Abd Eldaim, MA; Abdallah, AEM; Abdel-Daim, MM; Abdelaziz, SAM; Abdul Rashid, S; Abdullah, AS; Abdullah, LC; Abramson, MJ; Ahmed, HB; Ahmed, MM; Ahn, YC; Alexander, DC; Ando, T; Angelone, AM; Anglani, F; Ap, Y; Arthanari, SK; Axelrad, C; Bai, S; Bakonyi, P; Barnes, E; Beckmann, NA; Bélafi-Bakó, K; Bennett, CM; Bestha, RM; Bitsch, RG; Bradley, CA; Bu, Y; Calò, LA; Cañedo-Villaroya, E; Carlson, L; Caruso, S; Casado-Flores, J; Ceol, M; Cesarino, I; Chen, IL; Chen, R; Chen, X; Chilvers, MI; Cho, WK; Choong, TSY; Conceição-Neto, N; Culver, EL; Dai, X; de Lama Caro-Patón, G; De Rosa, I; Del Prete, D; Dharmage, SC; Dimitriadis, E; Dittakavi, S; Dobrowolski, JC; Edin, S; Elgarawany, GE; Emam, HE; Emmens, RW; Erbas, B; Erwich, JJHM; Farghali, M; Feng, L; Funston, RN; Gabler, NK; Gale, P; Ganesh, M; Gao, J; Gao, L; Gao, X; García-Salido, A; Gatto, R; Gautam, S; Ge, C; Ghogomu, SM; Gianesello, L; Gonçales, VR; Gooch, JL; Gooding, JJ; Gourley, GG; Gu, H; Gu, X; Gu, Z; Guerreri, M; Guillén, M; Hazzaa, SM; Heylen, E; Hicks, R; Hong, X; Hoshi, M; Hu, B; Hu, LX; Hu, R; Hu, S; Huang, J; Huang, K; Hubbard, WB; Hui, J; Hwang, NY; Iannacci, J; Ianus, A; Iglesias-Bouzas, MI; Ihara, I; Iwasaki, M; Jaeger, S; Kandel, YR; Karpińska, G; Kim, HK; Klopfenstein, TJ; Knorr, D; Koók, L; Kotb, S; Kruithof, S; Larsson, P; Laurence, C; Leng, J; Li, H; Li, J; Li, Q; Li, S; Li, X; Li, Z; Lian, J; Liang, JX; Liang, X; Lighaam, LC; Lin, CW; Lin, HC; Lin, J; Ling, A; Liu, J; Liu, P; Liu, YS; Ljuslinder, I; Lo, GH; Lodge, CJ; Löfgren-Burström, A; Lowe, AJ; Lu, M; Lu, N; Lucero-Prisno, DE; Luebbe, KM; Luo, X; Ma, Z; Maes, P; Makuch, M; Malekbala, MR; Mao, Z; Martínez-Romera, I; Marzo, G; Mathew, FM; Mattei, A; Matthijnssens, J; Mayumi, M; Morita, N; Mueller, DS; Mullangi, R; Mummolo, S; Murthi, P; Myte, R; Nabeshima, T; Nakamoto, K; Nehdi, IA; Nemestóthy, N; Niessen, HWM; Noh, JM; Nota, A; Nunes, D; Oh, D; Öhlund, D; Olsen, KM; Ono, H; Osawa, Y; Palmqvist, R; Palombo, M; Park, M; Patience, JF; Peng, Y; Perng, DS; Persano, A; Priante, G; Prince, SJ; Pulipati, S; Pyo, H; Qiu, X; Quan, J; Quaranta, F; Quinzi, V; Rademacher, CJ; Rajaraman, G; Rashid, U; Rauch, JC; Rector, A; Remmerswaal, EBM; Ren, R; Rispens, T; Rocha, GS; Saad, NM; Saito, K; Salamova, A; Sarfaraz, K; Satoshi, A; Schnellmann, RG; Scholpa, NE; Schonhoff, M; Schwartz, KJ; Schwarze, M; Schweer, WP; Seiichi, Y; Serrano-González, A; Severino, J; Shemesh, N; Shi, ZQ; Shike, DW; Shim, YM; Siciliano, PA; Siebenrock, KA; Silva, MKL; Smith, DL; Soltani, S; Song, YM; Spry, ML; Stalker, LA; Stokes, RS; Sullivan, PG; Sun, JM; Sun, S; Svanes, C; Syo, K; Tai, CM; Takashima, S; Tashita, C; Taurino, A; Ten Berge, IJM; Tenuta, AU; Teo, SH; Tilley, RD; Trivedi, RK; Umetsu, K; Unger, PA; van Bruggen, R; van Ham, SM; Van Ranst, M; Vanitha, J; Vekaria, HJ; Venier, M; Venkateshwaran, K; Venkert, A; Vermeulen, E; Wan, C; Wang, H; Wang, N; Wang, P; Wang, T; Wang, X; Wang, Y; Wise, KA; Wolbink, GJ; Wu, J; Wu, P; Wu, S; Wu, Y; Xia, Q; Xin, W; Xiong, Q; Xu, H; Xu, P; Xue, S; Yamamoto, Y; Yamashiro, T; Yan, F; Yan, H; Yan, S; Yan, Y; Yang, JM; Yang, L; Yang, P; Ye, W; Yeh, JH; Yinda, CK; Ying, GG; Ying, L; Yoon, HG; Yu, H; Zainuddin, M; Zakkula, A; Zeller, M; Zeng, Y; Zha, J; Zhang, F; Zhang, H; Zhang, M; Zhang, Q; Zhang, S; Zhang, T; Zhang, Z; Zhao, C; Zhao, J; Zhao, Y; Zhong, Q; Zhu, J; Zingmark, C; Zo, JI; Zou, Y | 1 |
| Adderley, T; Christopher, G; Irwin, MS; Kano, Y; Kee, L; Ladumor, Y; Ohh, M; Robinson, CM; Valencia-Sama, I | 1 |
| Chari, A; Cho, HJ; DeCastro, A; Jagannath, S; Landesman, Y; Madduri, D; Mouhieddine, TH; Parekh, S; Richter, J; Shah, J | 1 |
| Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ | 1 |
| Barra, G; Belli, V; Blauensteiner, B; Cardone, C; Ciaramella, V; Ciardiello, D; Ciardiello, F; Corte, CD; Cuomo, A; De Falco, V; Franco, R; Giunta, EF; Marino, FZ; Martinelli, E; Martini, G; Matrone, N; Mohr, T; Morgillo, F; Napolitano, S; Poliero, L; Selvaggi, F; Sibilia, M; Troiani, T; Vitiello, PP | 1 |
| Forsberg, P; Mark, TM; Sherbenou, D; Stalker, M | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Bar, N; Di, M; Giri, S; Huntington, SF; Parker, T; Patel, KK | 1 |
| Bakhshi, S; Caimi, P; Canales, M; Casasnovas, RO; Cavallo, F; Chamoun, K; Choquet, S; Corona, K; De la Cruz, F; Egyed, M; Follows, G; Goy, A; Gurion, R; Hamad, N; Hill, B; Jaeger, U; Kalakonda, N; Kauffman, MG; Ku, M; Kuruvilla, J; Ma, X; Maerevoet, M; Offner, F; Samal, P; Sancho, JM; Schuster, M; Shacham, S; Shah, J; Thieblemont, C; Van Den Neste, E; Vassilakopoulos, TP; Vermaat, JSP; Warzocha, K; Zijlstra, JM | 1 |
| Dolph, M; Leong, H; Tremblay, G | 1 |
| Ahern, TP; Borgquist, S; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Garber, JE; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; von Moos, R | 1 |
| Beale, PJ; Bonaventura, A; DeFazio, A; Friedlander, ML; Goh, JCH; Grant, PT; Hadley, AM; Mapagu, C; Martyn, J; McNally, OM; Mileshkin, LR; OʼConnell, RL; Scurry, J; Sjoquist, KM | 1 |
| Choi, YM; Kim, H; Kim, SH; Kim, SW; Ku, SY; Suh, CS | 1 |
| Ando, H; Kusunoki, S; Matsuoka, S; Ogishima, D; Ota, T; Sugimori, Y | 1 |
| Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G | 1 |
| Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y | 1 |
| Blok, EJ; Duijm-de Carpentier, M; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Rutgers, EJT; van de Velde, CJH; van den Bosch, J; van Leeuwen-Stok, AE | 1 |
| Bergh, J; Eloranta, S; Krawiec, K; Liljegren, A; Lissmats, A; Rodriguez-Wallberg, KA | 1 |
| Asano, Y; Goto, W; Hatano, T; Hirakawa, K; Kashiwagi, S; Motomura, H; Noda, S; Ohira, M; Onoda, N; Takada, K; Takashima, T; Tsujio, G | 1 |
| Baloglu, E; Chari, A; Cornell, RF; Gandhi, UH; Senapedis, W; Unger, TJ; Vogl, D | 1 |
| Adeegbe, DO; Bradner, JE; Buczkowski, K; Chen, T; Christensen, CL; Dries, R; Gao, P; Hammerman, PS; Han, S; Li, F; Li, Y; Liu, S; Liu, Y; Quayle, SN; Quinn, MM; Wang, X; Wong, KK; Zhang, H | 1 |
| Aljama, MA; Dingli, D; Sidiqi, MH | 1 |
| Altwerger, G; Ardighieri, L; Azodi, M; Bellone, S; Bianchi, A; Bignotti, E; Bonazzoli, E; Buza, N; Choi, J; Dong, W; Han, C; Huang, GS; Hui, P; Li, C; Lifton, RP; Litkouhi, B; Lopez, S; Manara, P; Manzano, A; Menderes, G; Odicino, F; Pecorelli, S; Pettinella, F; Ratner, E; Ravaggi, A; Riccio, F; Romani, C; Santin, AD; Schlessinger, J; Schwartz, PE; Silasi, DA; Todeschini, P; Wong, S; Yadav, G; Yang-Hartwich, Y; Zammataro, L; Zanotti, L; Zeybek, B; Zizioli, V | 1 |
| Boccardo, F; Bordonaro, R; Fini, A; Guglielmini, P; Massidda, B; Orzalesi, L; Porpiglia, M; Roagna, R; Rubagotti, A; Serra, P; Ucci, G | 1 |
| Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y | 1 |
| Goto, N; Hashimoto, M; Hatori, S; Inari, H; Iwasaki, H; Tanabe, H; Uesugi, K | 1 |
| Bachelot, T; Ben Larbi, S; Cohen, PA; Corbo, L; Ghayad, SE; Grisard, E; Heudel, PE; Treilleux, I; Vendrell, JA; Villedieu, M; Vilquin, P | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Bhan, AK; Binns, SN; Carney, E; Erlander, MG; Finkelstein, DM; Goss, PE; Ingle, JN; Muss, HB; Porter, P; Pritchard, KI; Rimm, DL; Schnabel, CA; Sgroi, DC; Shepherd, LE; Steffel, L; Szymonifka, J; Tu, D; Zarrella, E; Zhang, Y | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J | 1 |
| Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I | 1 |
| Cuzick, J; Dowsett, M; Dunbier, A; Erlander, MG; Goss, PE; Lopez-Knowles, E; Schnabel, CA; Schroeder, B; Sestak, I; Sgroi, DC; Sidhu, K; Zhang, Y | 1 |
| Badovinac-Crnjevic, T; Fan, L; Goss, PE; Strasser-Weippl, K | 1 |
| Goldhirsch, A | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Chai, J; Chen, D; Cheng, X; Jia, S; Li, T; Liang, L; Shen, Z; Sun, M; Yang, X | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Kawano, K; Tashima, Y | 1 |
| Esfahani, K; Ferrario, C; Le, P; Panasci, L | 1 |
| Krug, L; Lountzis, N; Shockman, S | 1 |
| Guseĭnov, KD; Livshits, MA; Vasil'ev, BV | 1 |
| Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Lopez-Knowles, E; Schaper, C; Sestak, I | 1 |
| Coleman, RL; Gershenson, DM; Jiang, Y; Johnston, T; Levenback, C; Lu, KH; Munsell, MF; Nowakowski, M; Ring, K; Slomovitz, BM; Soliman, PT; Yates, MS; Zhang, Q | 1 |
| Overmoyer, B | 1 |
| Bachelot, T; Cohen, PA; Corbo, L; Donini, CF; Grisard, E; Vendrell, JA; Villedieu, M; Vilquin, P | 1 |
| Dhillon, S | 1 |
| Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H | 1 |
| Azim, HA | 1 |
| Kuerer, H; Mitchell, KB | 1 |
| Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G | 1 |
| Horio, M; Ichihara, S; Inoue, T; Ishihara, Y; Ito, M; Kondo, I; Maeda, O; Matsumura, Y; Moritani, S; Sugiyama, K; Yamamoto, S | 1 |
| Ditzel, HJ; Elias, D; Knoop, AS; Lykkesfeldt, AE; Lyng, MB; Lænkholm, AV; Thomsen, KG; Vever, H | 1 |
| Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F | 1 |
| Johnston, SR | 1 |
| Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G | 1 |
| Kim, J; Oktay, K; Turan, V | 1 |
| Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N | 1 |
| Cuzick, J; Dowsett, M; Schnabel, CA; Schroeder, BE; Sestak, I; Sgroi, D; Zhang, Y | 1 |
| Bielski, CM; Boehm, JS; Cheah, JH; Church, AJ; Cima, MJ; Clemons, PA; Cowley, GS; Crompton, BD; Doshi, MB; Garraway, LA; Gill, S; Hahn, WC; Hong, AL; Howell, S; Imamovic, A; Janeway, KA; Jonas, O; Keskula, P; Kryukov, GV; Kynnap, BD; Langer, RS; Meyer, SC; Oh, C; Roberts, CW; Rodriguez-Galindo, C; Root, DE; Schreiber, SL; Shamji, AF; Stegmaier, K; Tseng, YY; Tsherniak, A; van Hummelen, P; Vazquez, F | 1 |
| Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Corrigan, MA; Jinih, M; O'Reilly, S; Redmond, HP; Relihan, N | 1 |
| Azim, AA; Costantini-Ferrando, M; Oktay, K | 1 |
| Bellone, S; McKenney, JK; Santin, AD; Shah, HR; Stone, PJ | 1 |
| Nagykálnai, T | 1 |
| Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N | 1 |
| Harbeck, N | 1 |
| Cella, D; Cuzick, J; Fallowfield, L; Sestak, I | 1 |
| Dos Reis, FJ; Ferriani, RA; Filho, FM; Martins, WP; Nastri, CO | 1 |
| Boyle, F; Forbes, J | 1 |
| Cianfrocca, M | 1 |
| Callam, M; Glen, J; Thomas, RJ; Williams, M | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K | 1 |
| Beiner, M; Ben-Baruch, G; Davidzon, T; Fridman, E; Korach, J; Perri, T | 1 |
| Alberts, DS; Bartels, HG; Bartels, PH; Montironi, R; Scarpelli, M | 1 |
| Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G | 1 |
| Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B | 1 |
| Liu, S; Redman, CW; Todd, RW; Tzakas, E | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Beriwal, S; Bhargava, R; Dabbs, DJ; O'Connor, SM | 1 |
| Baehner, FL; Baum, M; Bugarini, R; Buzdar, A; Cuzick, J; Dowsett, M; Dunbier, A; Forbes, J; Howell, A; Mallon, EA; Quinn, E; Salter, J; Shak, S; Wale, C | 1 |
| Gradishar, WJ | 1 |
| Ikeda, Y; Kawana, K; Kozuma, S; Nakagawa, S; Oda, K; Shoji, K; Takazawa, Y; Taketani, Y; Yasugi, T | 1 |
| Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G | 1 |
| Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Kaminsky, A; Khalid, MK; Labban, G; Parda, D; Trombetta, MG; Valakh, V; Werts, ED | 1 |
| Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Iorfida, M; Luini, A; Montagna, E; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Fisher, C; Jones, RL; Judson, IR; Ratnayake, G; Scurr, M; Thway, K | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S | 1 |
| Chirgwin, J; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, R; Pienkowski, T; Price, KN; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H | 1 |
| Doughty, JC | 1 |
| Chu, QS; Steed, HL | 1 |
| Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Bathini, V; Buttar, A; Khan, A; Mittal, K | 1 |
| Allawi, Z; Baum, M; Cuzick, J | 1 |
| Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Frederix, GW; Hövels, AM; Raaijmakers, JA; Schellens, JH; Severens, JL | 1 |
| Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C | 1 |
| Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN | 1 |
| Kelly, CM; Pritchard, KI | 1 |
| Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D | 1 |
| Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Bane, F; Byrne, C; Conroy, RM; Gaora, PÓ; Hao, Y; Hill, AD; McBryan, J; McIlroy, M; O'Hara, J; Tibbitts, P; Vareslija, D; Young, LS | 1 |
| Abdul Munem, A; Al-Bahrani, B; Kamona, A; Mehdi, I; Nadas, AM | 1 |
| Stanton, V | 1 |
| Abraham, J; Caldas, C; Pharoah, PD | 1 |
| Cox, NJ; Flockhart, DA; Kroetz, DL; McLeod, HL; Nakamura, Y; Ratain, MJ | 1 |
| Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B | 1 |
| Berruti, A; Dogliotti, L; Familiari, U; Gorzegno, G; Sperone, P | 1 |
| Faulds, DM; Wellington, K | 1 |
| Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T | 1 |
| Chiba, N; Mori, K; Yamamoto, Y; Yonekawa, H | 1 |
| Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P | 1 |
| Höffken, K; Sayer, HG | 1 |
| Cuzick, J | 3 |
| Kmietowicz, Z | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T | 1 |
| Buzdar, AU | 2 |
| Figg, WD; Hussain, MM; Kohn, EC; Kotz, H; Minasian, L; Oliver, VK; Premkumar, A; Raggio, M; Reed, E; Sarosy, G; Steinberg, SM; Zhai, S | 1 |
| Twombly, R | 1 |
| Altundag, K; Altundag, O | 1 |
| Runowicz, CD | 1 |
| DeGrendele, H | 1 |
| Hietanen, P; Mäkelä, M | 1 |
| Harris, SR | 1 |
| Dimopoulos, MA; Efstathiou, E; Grimani, I; Hamilos, G; Markaki, S; Papadimitriou, CA; Siapkaras, J; Vlachos, G; Zorzou, M | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Blanchard, R; Hamid, AM; Leiser, AL | 1 |
| Hillner, BE | 1 |
| Davis, GJ; Ravdin, PM | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K | 1 |
| Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M | 1 |
| Amy, JJ; Bourgain, C; Breugelmans, M; De Sutter, P; Leunen, M | 1 |
| Dowsett, M | 1 |
| Harwood, KV | 1 |
| Travis, K | 1 |
| Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Jakesz, R | 1 |
| Kahán, Z | 1 |
| Kaufmann, M; Rody, A | 2 |
| Baum, M | 1 |
| Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C | 1 |
| Burhenne, J; Foell, JL; Reiss, T; Rengelshausen, J; Staege, MS; Stiefel, M; Wawer, A | 1 |
| Sereda, D; Werth, VP | 1 |
| Tuma, RS | 1 |
| Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J | 1 |
| Hargis, JB; Nakajima, ST | 1 |
| Rocchi, A; Verma, S | 1 |
| Forbes, JF | 1 |
| Goss, PE | 2 |
| Dixon, JM | 1 |
| Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC | 1 |
| Freeman, SA; Modesitt, SC | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 1 |
| Borstnar, S; Cufer, T; Mrhar, A; Piskur, P; Sonc, M | 1 |
| Annemans, L; Moeremans, K | 1 |
| Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C | 1 |
| Dobrowsky, W; Huigol, NG; Jayatilake, RS; Kagiya, VT; Kizilbash, NI; Okkan, S; Tatsuzaki, H | 1 |
| Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K | 1 |
| Castiglione-Gertsch, M; Coates, AS; Debled, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Láng, I; Mauriac, L; Monnier, A; Mouridsen, H; Nogaret, JM; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Viale, G; Wardley, A; Zabaznyi, N | 1 |
| Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Fukutomi, T; Hasegawa, T; Kinoshita, T; Omatsu, M; Seki, K; Shien, T; Shimizu, C; Terada, K | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Gelmon, K | 1 |
| Gabra, H; Gourley, C; Langdon, SP; MacKean, MJ; Mano, M; McCurdy, J; McMahon, T; Nafussi, AA; Reed, N; Rye, R; Rye, T; Smyth, JF; Stevenson, A; Stewart, M; Vasey, P; Walker, G; Williams, AR | 1 |
| Barghout, V; Delea, T; Karnon, J | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Cufer, T | 1 |
| Haidinger, R; Harbeck, N | 1 |
| Ellis, M; Ma, C | 1 |
| Dodwell, D; Williamson, D | 1 |
| Altundag, K; Dizdar, O; Harputluoglu, H | 1 |
| Wengström, Y | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS | 1 |
| Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N | 1 |
| Pennery, E | 1 |
| Alkasi, O; Beckmann, MW; Fasching, P; Jonat, W; Maass, N; Meinhold-Heerlein, I; Zaki, R | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Detre, S; Dowsett, M; Grimshaw, R; Lee, K; Macaulay, VM; Rowlands, M | 1 |
| Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL | 1 |
| Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J | 1 |
| Cohen, Y; Geffen, DB; Lavrenkov, K; Man, S | 1 |
| Illiger, HJ | 1 |
| Abe, R; Ikeda, S; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H | 1 |
| Ravdin, P | 1 |
42 review(s) available for triazoles and Local Neoplasm Recurrence
| Article | Year |
|---|---|
How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodiazepines; Consolidation Chemotherapy; Humans; Hydrazines; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Radiotherapy; Receptors, Chimeric Antigen; Stem Cell Transplantation; Treatment Failure; Triazoles | 2021 |
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Hypothyroidism; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2023 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome; Triazoles | 2018 |
Therapy for relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Decision Making; Gene Expression Profiling; Humans; Hydrazines; Immunotherapy; In Situ Hybridization, Fluorescence; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Sulfonamides; Symptom Assessment; Transplantation, Autologous; Triazoles; Watchful Waiting | 2018 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Long-Term Care; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Awards and Prizes; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus Development Conferences as Topic; Disease-Free Survival; Female; Genes, erbB-2; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Precision Medicine; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Switzerland; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurrence, Local; Nitriles; Time Factors; Triazoles | 2014 |
Palbociclib: first global approval.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Approval; Drug Interactions; Drugs, Investigational; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Triazoles; United States; United States Food and Drug Administration | 2015 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Mammography; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Precision Medicine; Prognosis; Radiotherapy, Adjuvant; Tamoxifen; Triazoles | 2015 |
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Treatment Outcome; Triazoles | 2016 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2017 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Never too late: reducing late breast cancer relapse risk.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Europe; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles | 2009 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?
Topics: Aromatase Inhibitors; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2011 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles | 2012 |
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Topics: Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Tomography, X-Ray Computed; Triazoles | 2012 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Enzyme Inhibitors; Female; Half-Life; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Time Factors; Triazoles | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Recurrence; Survival Rate; Tamoxifen; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Topics: Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2006 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
Prescribing extended adjuvant letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2007 |
The patient experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Patient Education as Topic; Postmenopause; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Femara and the future: tailoring treatment and combination therapies with Femara.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2007 |
Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Arthralgia; Atrophy; Breast Neoplasms; Cardiovascular Diseases; Comorbidity; Female; Hot Flashes; Humans; Lubricants; Neoplasm Recurrence, Local; Nitriles; Patient Education as Topic; Quality of Life; Tamoxifen; Triazoles; Vagina; Weight Gain | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
The control and biological importance of intratumoural aromatase in breast cancer.
Topics: Adenocarcinoma; Androgens; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Male; Mice; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Triazoles; Tumor Cells, Cultured | 1996 |
58 trial(s) available for triazoles and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Triazoles | 2021 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2023 |
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2023 |
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2020 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Etoposide; Humans; Hydrazines; Ifosfamide; Lymphoma, T-Cell; Neoplasm Recurrence, Local; Triazoles | 2021 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Topics: Age Factors; Aged; Humans; Hydrazines; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome; Triazoles | 2021 |
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Topics: Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2017 |
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nitriles; Organoplatinum Compounds; Ovarian Neoplasms; Prospective Studies; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Tissue Array Analysis; Triazoles | 2017 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2018 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Triazoles | 2014 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Data Interpretation, Statistical; Female; Follow-Up Studies; Hormones; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Regression Analysis; Risk; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumor; Cohort Studies; Disease-Free Survival; DNA Mutational Analysis; Endometrial Neoplasms; Endometriosis; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunosuppressive Agents; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2015 |
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2016 |
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counseling; Cryopreservation; Disease-Free Survival; Female; Fertility; Fertilization in Vitro; Gonadotropins; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Ovulation Induction; Prospective Studies; Triazoles | 2008 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; United Kingdom | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Tamoxifen; Triazoles | 2009 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genetic Testing; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2010 |
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Second Primary; New Zealand; Nitriles; North America; Postmenopause; Proportional Hazards Models; Receptors, Steroid; Risk Factors; Selective Estrogen Receptor Modulators; South Africa; South America; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2012 |
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D1; Female; Follow-Up Studies; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Obesity; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate; Triazoles | 2003 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Switzerland; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Calcium Channel Blockers; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles | 2003 |
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; CA-125 Antigen; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Oligonucleotide Array Sequence Analysis; Patient Care Planning; Prognosis; Tamoxifen; Triazoles | 2004 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2005 |
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Topics: Aged; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
Topics: Adult; Aged; Brachytherapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Treatment Outcome; Triazoles; Uterine Cervical Neoplasms | 2007 |
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Radiotherapy Dosage; Survival Rate; Tamoxifen; Triazoles | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Triazoles | 2007 |
Letrozole in the extended adjuvant setting: MA.17.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Quality of Life; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome; Triazoles | 2008 |
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2000 |
[Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Survival Rate; Tamoxifen; Triazoles | 2002 |
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Rate; Triazoles | 2002 |
112 other study(ies) available for triazoles and Local Neoplasm Recurrence
| Article | Year |
|---|---|
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Triazoles | 2021 |
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
Topics: Apoptosis; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Neoplasm Recurrence, Local; Nitriles; Pterocarpans; Triazoles | 2022 |
Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Karyopherins; Multidrug Resistance-Associated Proteins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Triazoles | 2022 |
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor.
Topics: Aniline Compounds; Animals; Female; Fibrocystic Breast Disease; Fibronectins; Fibrosis; Humans; Mice; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Oxidative Stress; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; Transforming Growth Factor beta; Transforming Growth Factors; Triazoles | 2022 |
Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?
Topics: Endometrial Neoplasms; Female; Humans; Hydrazines; Neoplasm Recurrence, Local; Triazoles; Tumor Suppressor Protein p53 | 2023 |
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib | 2020 |
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
Topics: Adenocarcinoma; Aged; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Computational Biology; Databases, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Signal Transduction; Spheroids, Cellular; Triazoles | 2021 |
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Homologous; Treatment Outcome; Triazoles | 2021 |
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Triazoles | 2021 |
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Boston; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Conservative Treatment; Cryopreservation; Embryo Transfer; Endometrial Neoplasms; Female; Fertility Preservation; Fertilization in Vitro; Humans; Letrozole; Levonorgestrel; Live Birth; Megestrol Acetate; Neoplasm Recurrence, Local; Nitriles; Pregnancy; Pregnancy Outcome; Triazoles | 2018 |
Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata.
Topics: Adult; Aromatase Inhibitors; Female; Humans; Leiomyomatosis; Letrozole; Neoplasm Recurrence, Local; Nitriles; Pelvic Neoplasms; Peritoneal Cavity; Triazoles | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2017 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Risk Factors; Tamoxifen; Triazoles | 2018 |
Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
Topics: Adult; Breast Neoplasms; Cohort Studies; Female; Fertility Preservation; Humans; Infertility, Female; Neoplasm Recurrence, Local; Ovulation Induction; Proportional Hazards Models; Risk Factors; Sweden; Triazoles | 2018 |
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Mammaplasty; Mastectomy; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nitriles; Treatment Outcome; Triazoles | 2017 |
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacetylase 6; Humans; Hydroxamic Acids; Killer Cells, Natural; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Proteins; Pyrimidines; RNA, Small Interfering; Small Cell Lung Carcinoma; Synthetic Lethal Mutations; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Topics: Animals; Antineoplastic Agents; Azepines; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proteins; Proto-Oncogene Proteins c-myc; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2019 |
[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Incidence; Letrozole; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Interleukin; Receptors, Interleukin-17; Receptors, Progesterone; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Triazoles | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk; Tamoxifen; Triazoles | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transcription Factors; Treatment Outcome; Triazoles | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Growth Processes; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Signal Transduction; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma.
Topics: Carcinoma, Adenoid Cystic; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Movement; Chemokine CCL5; Cyclohexanes; Humans; Maraviroc; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peripheral Nerves; Receptors, CCR5; Salivary Gland Neoplasms; Triazoles | 2014 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Risk; Risk Assessment; Tamoxifen; Transcriptome; Treatment Outcome; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Splenectomy; Splenic Neoplasms; Triazoles | 2014 |
Remission of metastatic primary mucinous carcinoma of the skin with anastrozole.
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Female; Head and Neck Neoplasms; Humans; Mohs Surgery; Neoplasm Recurrence, Local; Nitriles; Remission Induction; Scalp; Skin Neoplasms; Treatment Failure; Triazoles | 2014 |
[The use of letrozole in ovarian cancer].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Treatment Outcome; Triazoles | 2014 |
Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2015 |
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cluster Analysis; Cohort Studies; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; MicroRNAs; Neoplasm Recurrence, Local; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Triazoles | 2015 |
Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2015 |
Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Sarcoma, Endometrial Stromal; Survivors; Tomography, X-Ray Computed; Triazoles; Young Adult | 2015 |
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Eye Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Peptides; Receptors, Estrogen; Retrospective Studies; RGS Proteins; Transcription Factors; Treatment Outcome; Trefoil Factor-3; Triazoles | 2015 |
Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2016 |
Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Drug Therapy, Combination; Female; Fertility; Fertility Preservation; Gonadotropins; Humans; Letrozole; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nitriles; Ovulation Induction; Prospective Studies; Survival Rate; Treatment Outcome; Triazoles | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; Health Status Indicators; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2016 |
Integrated genetic and pharmacologic interrogation of rare cancers.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; CRISPR-Cas Systems; Cyclin-Dependent Kinase 4; Doxorubicin; Drug Screening Assays, Antitumor; Exome; Exportin 1 Protein; Female; Genomics; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Piperazines; Pyridines; Rare Diseases; Receptors, Cytoplasmic and Nuclear; RNA Interference; Sarcoma; Sequence Analysis, RNA; Triazoles | 2016 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Protective Factors; Proto-Oncogene Proteins; Risk Factors; Treatment Outcome; Triazoles | 2017 |
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Radiography; Triazoles | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neoplasms; Female; Hot Flashes; Humans; Joints; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Vasomotor System | 2008 |
Sonographic evaluation of endothelial function in letrozole and tamoxifen users.
Topics: Aged; Aromatase Inhibitors; Brachial Artery; Breast Neoplasms; Carotid Artery, External; Case-Control Studies; Endothelium, Vascular; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
Breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk; Time Factors; Triazoles | 2008 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Ovariectomy; Prognosis; Treatment Outcome; Triazoles | 2009 |
Knowledge discovery processing and data mining in karyometry.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Papillary; Cell Nucleus; Colonic Neoplasms; Computational Biology; Female; Humans; Karyometry; Letrozole; Neoplasm Recurrence, Local; Nitriles; Precancerous Conditions; Triazoles; Urinary Bladder Neoplasms | 2009 |
Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS).
Topics: Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Sarcoma, Endometrial Stromal; Treatment Outcome; Triazoles | 2009 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection of Cancer; Female; Gonadal Steroid Hormones; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles | 2010 |
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Endometrial Stromal Tumors; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2011 |
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pennsylvania; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors; Triazoles | 2011 |
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Polyethylene Glycols; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles; Tumor Burden | 2011 |
Fungal spinal cord compression in metastatic synovial sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Fractures, Spontaneous; Humans; Lung Neoplasms; Mycoses; Neoplasm Recurrence, Local; Neoplasm Staging; Osteomyelitis; Pneumonectomy; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma, Synovial; Spinal Cord Compression; Spinal Cord Neoplasms; Triazoles; Voriconazole | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effective role of hormonal therapy in metastatic primary neuroendocrine breast carcinoma.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Surgical Procedures, Operative; Tamoxifen; Triazoles; Wounds and Injuries | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Female; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Risk Factors; Tamoxifen; Triazoles; United Kingdom | 2012 |
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
Topics: Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Letrozole; MAP Kinase Signaling System; Neoplasm Recurrence, Local; Nitriles; Nuclear Receptor Coactivator 3; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-myc; Transcription, Genetic; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins; Up-Regulation | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Reversible pancytopenia caused by oral letrozole assumption in a patient with recurrent breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pancytopenia; Triazoles | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Cyclophosphamide; Doxorubicin; Drainage; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pleural Effusion, Malignant; Pleurisy; Triazoles | 2002 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Doctors test drug to prevent cancer in high risk women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Triazoles | 2003 |
Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Estrogen Receptor Modulators; Ethics, Research; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Single-Blind Method; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2003 |
Breast-cancer drug letrozole picks up where tamoxifen leaves off. But we don't know who stands to benefit the most from this follow-up approach.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
New treatment boosts outlook for breast cancer survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Progestins; Prolactin; Sarcoma, Endometrial Stromal; Triazoles | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Middle Aged; Models, Theoretical; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cholesterol; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Triazoles | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Survival Rate; Triazoles | 2004 |
Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Sarcoma, Endometrial Stromal; Triazoles | 2004 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
[Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Planning; Patient Satisfaction; Patient Selection; Predictive Value of Tests; Quality of Life; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Tamoxifen; Triazoles | 2004 |
Alternative to tamoxifen effective for preventing breast cancer recurrence.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2005 |
Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma.
Topics: Administration, Oral; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus fumigatus; Brain Abscess; Carboplatin; Cerebral Ventricle Neoplasms; Child; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cyclophosphamide; Diagnostic Errors; Etoposide; Humans; Immunocompromised Host; Infusions, Intravenous; Lomustine; Male; Medulloblastoma; Methotrexate; Neoplasm Recurrence, Local; Neuroaspergillosis; Pyrimidines; Surgical Wound Infection; Triazoles; Vincristine; Voriconazole | 2007 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Antagonists; Exanthema; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Skin; Tamoxifen; Triazoles | 2006 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2005 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female; Humans; Letrozole; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome; Triazoles | 2006 |
Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Menstruation; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles; United States | 2006 |
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Economics, Pharmaceutical; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Slovenia; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; British Columbia; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Risk Factors; Survival Rate; Tamoxifen; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom | 2008 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2007 |
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Female; Goserelin; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nitriles; Sarcoma, Endometrial Stromal; Triazoles | 2009 |
Endometrial stromal sarcoma: objective response to letrozole.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pelvic Neoplasms; Sarcoma, Endometrial Stromal; Triazoles | 2001 |
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Retrospective Studies; Survival Analysis; Triazoles | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |